|
2018 Journal Article Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumorsSingh, Simron, Moody, Lesley, Chan, David L., Metz, David C., Strosberg, Jonathan, Asmis, Timothy, Bailey, Dale L., Bergsland, Emily, Brendtro, Kari, Carroll, Richard, Cleary, Sean, Kim, Michelle, Kong, Grace, Law, Calvin, Lawrence, Ben, McEwan, Alexander, McGregor, Caitlin, Michael, Michael, Pasieka, Janice, Pavlakis, Nick, Pommier, Rodney, Soulen, Michael, Wyld, David and Segelov, Eva (2018). Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncology, 4 (11), 1597-1604. doi: 10.1001/jamaoncol.2018.2428 |
|
2018 Conference Publication Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experienceBryant, Geoffrey, Thaker, Darshit, Wyld, David, Leach, Justine, Wheatley, Hermione and Garth, Vanessa (2018). Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experience. HOBOKEN: WILEY. |
|
2018 Conference Publication Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland?Moore, Julie, Dunn, Nathan, Tran, Nancy and Wyld, David (2018). Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland?. HOBOKEN: WILEY. |
|
2018 Journal Article Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survivalDumbrava, Monica I., Burmeister, Elizabeth A., Wyld, David, Goldstein, David, O'Connell, Dianne L., Beesley, Vanessa L., Gooden, Helen M., Janda, Monika, Jordan, Susan J., Merrett, Neil D., Payne, Madeleine E., Waterhouse, Mary A. and Neale, Rachel E. (2018). Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. Asia Pacific Journal of Clinical Oncology, 14 (4), 326-336. doi: 10.1111/ajco.12862 |
|
2018 Journal Article Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancerLadwa, Rahul, Kalas, Timothy, Pathmanathan, Shivanshan, Woodward, Natasha, Wyld, David and Sanmugarajah, Jasotha (2018). Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer. Clinical Breast Cancer, 18 (5), e1181-e1187. doi: 10.1016/j.clbc.2018.04.016 |
|
2018 Journal Article Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumoursBeesley, Vanessa L., Burge, Matthew, Dumbrava, Monica, Callum, Jack, Neale, Rachel E. and Wyld, David K. (2018). Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Supportive Care in Cancer, 26 (9), 3153-3161. doi: 10.1007/s00520-018-4166-5 |
|
2018 Journal Article Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumorsLadwa, Rahul, Wen Hong, Hooi, Wyld, David, Pattison, David A. and Burge, Matthew (2018). Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors. Clinical Nuclear Medicine, 43 (3), 186-187. doi: 10.1097/RLU.0000000000001970 |
|
2018 Journal Article MyD88 and TLR4 expression in epithelial ovarian cancerBlock, Matthew S., Vierkant, Robert A., Rambau, Peter F., Winham, Stacey J., Wagner, Philipp, Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G., Taran, Florin Andrei, Sinn, Peter, Sieh, Weiva, Sharma, Raghwa, Rothstein, Joseph H., Ramón y Cajal, Teresa, Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Ness, Roberta B., Nelson, Gregg, Modugno, Francesmary, Menkiszak, Janusz, McGuire, Valerie, McCauley, Bryan M., Mack, Marie, Lubiński, Jan, Longacre, Teri A., Li, Zheng, Lester, Jenny, Kennedy, Catherine J. ... Goode, Ellen L. (2018). MyD88 and TLR4 expression in epithelial ovarian cancer. Mayo Clinic Proceedings, 93 (3), 307-320. doi: 10.1016/j.mayocp.2017.10.023 |
|
2018 Journal Article Correction: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: Results from the STEP study [BMC Cancer., 17, (2017) (715)] DOI: 10.1186/s12885-017-3733-3Chan, Raymond Javan, Yates, Patsy, Li, Qiuping, Komatsu, Hiroko, Lopez, Violeta, Thandar, Myat, Chacko, Selva Titus, So, Winnie Kwok Wei, Pongthavornkamol, Kanaungnit, Yi, Myungsun, Pittayapan, Pongpak, Butcon, Jesson, Wyld, David and Molassiotis, Alex (2018). Correction: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: Results from the STEP study [BMC Cancer., 17, (2017) (715)] DOI: 10.1186/s12885-017-3733-3. BMC Cancer, 18 (1) 240, 1-1. doi: 10.1186/s12885-018-4105-3 |
|
2018 Conference Publication Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Journal Article BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibitionMoujaber, Tania, Etemadmoghadam, Dariush, Kennedy, Catherine J., Chiew, Yoke-Eng, Balleine, Rosemary L., Saunders, Catherine, Wain, Gerard V., Gao, Bo, Hogg, Russell, Srirangan, Sivatharsny, Kan, Casina, Fereday, Sian, Traficante, Nadia, Patch, Ann-Marie, Pearson, John V., Waddell, Nicola, Grimmond, Sean M., Dobrovic, Alexander, Bowtell, David D.L., Harnett, Paul R., deFazio, Anna, Bowtell, D., Chenevix-Trench, G., Green, A., Webb, P., DeFazio, A., Gertig, D., Traficante, N., Fereday, S. ... Zeps, N. (2018). BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition. JCO Precision Oncology, 2 (2), 1-14. doi: 10.1200/PO.17.00221 |
|
2018 Conference Publication How the rare see their care: Perceptions of care and patient reported outcomes in people living with neuroendocrine tumoursWyld, D., Burge, M., Dumbrava, M., Callum, J., Neale, R. and Beesley, V. (2018). How the rare see their care: Perceptions of care and patient reported outcomes in people living with neuroendocrine tumours. Victorian Cancer Survivorship Conference, Melbourne, Australia, 8 -9 February 2018. |
|
2018 Conference Publication How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine TumorsWyld, D., Burge, M., Dumbrava, M., Callum, J., Neale, R. and Beesley, V. (2018). How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: Karger. doi: 10.1159/000487699 |
|
2018 Conference Publication Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumorLadwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Colorectal cancer patient reported outcomes: putting theory into practiceBryant, Geoffrey, Eastgate, Melissa, Wyld, David, Burge, Matthew, Thaker, Darshit and Busato, Matthew (2018). Colorectal cancer patient reported outcomes: putting theory into practice. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth Convention and Exhibition Centre, 13–15 November 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Dietary patterns and attitudes in cancer survivorsLee, Shu Fen , Wyld, David , Eastgate, Melissa and Brown, Teresa (2018). Dietary patterns and attitudes in cancer survivors. Victorian Cancer Survivorship Conference, Melbourne, Australia, 8-9 February 2018. |
|
2018 Conference Publication Neuroendocrine Neoplasm Trends Over 32 Years in Queensland, AustraliaWan, Mark H., Moore, Julie and Wyld, David K. (2018). Neuroendocrine Neoplasm Trends Over 32 Years in Queensland, Australia. Princess Margaret Cancer Conference. Accelerating Precision Medicine 2018, Toronto Canada, January 19 2018. |
|
2018 Journal Article Biliary stenting in patients with pancreatic cancer: results from a population-based cohort studyPayne, Madeleine, Burmeister, Elizabeth A., Waterhouse, Mary, Jordan, Susan J., O'Connell, Dianne L., Merrett, Neil D., Goldstein, David, Wyld, David, Beesley, Vanessa L., Gooden, Helen, Janda, Monika and Neale, Rachel E. (2018). Biliary stenting in patients with pancreatic cancer: results from a population-based cohort study. Pancreas, 47 (1), 80-86. doi: 10.1097/MPA.0000000000000960 |
|
2018 Conference Publication Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumorsLadwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabineVan der Zwan, W., Wyld, D., Brabander, T., Teunissen, J., Kam, B., MacFarlane, D., Krenning, E., Kwekkeboom, D. and de Herder, W. (2018). A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7 - 9 March 2018. Basel, Switzerland: S. Karger AG. |
